TuHURA Biosciences CFO granted 273,696 stock options

TuHURA Biosciences, Inc. reported an insider equity award for its Chief Financial Officer, Dan Dearborn.

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. reported an insider equity award for its Chief Financial Officer, Dan Dearborn. On January 6, 2026, he was granted 273,696 options (right to buy common stock) with an exercise price of $0.73 per share, expiring on January 6, 2036. The options were acquired at no cost and are held directly. According to the footnote, this is a supplemental option grant to an option grant previously made in December 2025, and one-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.

Insider Trade Summary

Grant/Award: 273,696 shares

Grant/Award 1 txn

Insider Dearborn Dan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	273,696	$0.00	$0.00

Holdings After Transaction: Options (Right to Buy) — 273,696 contracts (Direct)

Footnotes (1)

1. F1. Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TuHURA Biosciences (HURA) disclose?

TuHURA Biosciences disclosed that its Chief Financial Officer, Dan Dearborn, received a grant of 273,696 stock options on January 6, 2026.

What are the key terms of the TuHURA Biosciences CFO option grant?

The CFO was granted 273,696 options with an exercise price of $0.73 per share, expiring on January 6, 2036, and acquired them at a price of $0.

How do the TuHURA Biosciences CFO stock options vest?

According to the footnote, one-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.

Is the TuHURA Biosciences CFO option grant related to a prior award?

Yes. The filing states the grant represents a supplemental option grant to an option grant previously made in December 2025.

How many derivative securities does the TuHURA Biosciences CFO hold after this grant?

Following the reported transaction, the CFO beneficially owns 273,696 derivative securities (options) directly.

What form was used to report the TuHURA Biosciences CFO option grant?

The transaction was reported on Form 4, which discloses changes in beneficial ownership of company securities by insiders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dearborn Dan

(Last) (First) (Middle)

10500 UNIVERSITY CENTER DRIVE

SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.73	01/06/2026		A		273,696		(1)	01/06/2036	Common Stock	273,696	$0	273,696	D

Explanation of Responses:

1. Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.

	/s/ Dan Dearborn	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.